Nilotinib With Radiation for High Risk Chordoma

Status Active, not recruiting

Clinical Trial Summary

The study drug, Nilotinib, is believed to slow down tumor growth by regulating a gene involved in cellular growth of chordoma cells. During this research study, subjects will also receive radiation therapy which is considered a standard treatment for advanced chordomas. It is hoped by adding nilotinib, the benefits of radiation therapy can be enhanced without adding significant toxicities. The purpose of this research study is to determine the safety of nilotinib when used in combination with radiation therapy, and the highest dose of nilotinib that can be given safely with radiation therapy.

Clinical Trial Description

Nilotinib will be taken orally daily in two cycles of 28 days each. Two weeks after taking nilotinib, subjects will begin radiation therapy. Radiation therapy will continue every weekday until Day 56 of the study. If it is determined that the subject's tumor cannot be removed by surgery, an additional 3 weeks of radiation therapy will be applied after Day 56 of the study. During study visits subjects will have physical exams, routine blood tests, urine and blood clotting tests, and EKGs. Subjects will also have tumor assessment by chest CT and MRI or CT of the tumor at screening, on approximately Day 56 of the study, then every 6 months for one year and then annually thereafter if ther is no disease progression. ;

Study Design

Related Conditions & MeSH terms

Chordoma

Clinical Trial Details

NCT number	NCT01407198
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	August 2011
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03955042` - Pemetrexed for the Treatment of Chordoma	Phase 1
Completed	`NCT01347307` - Stereotactic Body Radiotherapy for Spine Tumors	N/A
Active, not recruiting	`NCT00496119` - Proton Beam Therapy for Chordoma Patients	Phase 2
Recruiting	`NCT06029218` - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy	N/A
Completed	`NCT03595228` - BN Brachyury and Radiation in Chordoma	Phase 2
Recruiting	`NCT06140732` - Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma	Phase 2
Active, not recruiting	`NCT01175109` - Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma	Phase 1
Completed	`NCT00150072` - Efficacy and Safety of Imatinib in Chordoma	Phase 2
Terminated	`NCT00003926` - Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors	Phase 1
Recruiting	`NCT05041127` - Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma	Phase 2
Recruiting	`NCT05861245` - Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base	N/A
Completed	`NCT00464620` - Trial of Dasatinib in Advanced Sarcomas	Phase 2
Completed	`NCT02383498` - QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma	Phase 2
Recruiting	`NCT03242382` - Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.	Phase 2
Completed	`NCT02520128` - A Study of IMRT in Primary Bone and Soft Tissue Sarcoma	N/A
Recruiting	`NCT01567046` - Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas	N/A
Recruiting	`NCT02986516` - Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease	N/A
Completed	`NCT00919269` - Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Active, not recruiting	`NCT02989636` - Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma	Phase 1
Active, not recruiting	`NCT03083678` - Afatinib in Locally Advanced and Metastatic Chordoma	Phase 2